Cannabis Science Enters into Investor Relations Agreement
SAN FRANCISCO--(BUSINESS WIRE)-- Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging cannabis pharmaceutical company, is pleased to announce that the company has retained Catalyst Xchange Corp. (CXC), located in London, Ontario, to provide it with investor relations services under an agreement dated June 30, 2009. Represented by its principals, Don Shaxon and Jason Springett, CXC will provide a variety of promotional and investor relations services to CSI, including assisting with the dissemination of news and information to the public, and, initiating and maintaining contact with investors. As part of its services CXC uses social networking and Internet-based marketing sites.
"We are very pleased to be on board with Cannabis Science for the long run," Don Shaxon from Catalyst Xchange Corp. indicated. "We thoroughly understand the multi-billion dollar pharmaceutical market that the company seeks to enter. Fortunately, Cannabis Science understands it as well and is positioning itself with cannabis-based products, which some hail as the next class of pharmaceutical blockbusters. Cannabis Science has hired the right people, Ray Carr, R.Ph., and Mary Ruwart, Ph.D., to head up the efforts to get the company's unique cannabis-based pharmaceuticals through the FDA approval process. We are focused on immediately assisting this effort by raising share value and investment capital for the company."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward-Looking Statement
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," "intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.